Details

Autor(en) / Beteiligte

• Zhu, Zhen
• Lu, Zhaohui
• Xu, Tianmin
• Chen, Cong
• Yang, Gang
• Zha, Tao
• Lu, Jianchun
• Xue, Yuan

Titel

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Ist Teil von

• The Journal of infection, 2020-07, Vol.81 (1), p.e21-e23

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• •On day 14 after the admission, no viral load was detected in arbidol group.•44.1% of patients in lopinavir/ritonavir group had positive RNA test on day 14.•Patients in the arbidol group had a shorter duration of positive RNA test.•No apparent side effects were found in both groups.•Arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19. Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.